Remedium Capital Partners, LLC holds a concentrated book of 6 stocks worth $281.2M as of Q1 2026 (disclosed May 19, 2026, a ~45-day 13F lag). Their largest long position is ORUKA THERAPEUTICS INC at 27% of the equity book.
The public view is the crawlable proof. The same sourced dataset is available through REST and MCP for agents, research scripts, and back-office tools.
This fund page is the Follow view. The Build view lets your agent pull holdings, quarter changes, overlap, and source filings through API or MCP.
curl -H "Authorization: Bearer YOUR_API_KEY" \ "https://arkolith.com/api/v1/funds/2104501/holdings"
Use Arkolith to show Remedium Capital Partners, LLC's latest holdings, largest changes, and filing provenance.
Top-heavy: concentrated book
Share of the disclosed book in its largest positions. A higher top-5 share means a more concentrated, higher-conviction portfolio.
35% mapped to company sectors
Direct operating-company sectors from our SIC-based security master. ETF/fund and unclassified holdings stay visible separately; this is not ETF look-through exposure.
Estimated $ traded · quarter-end prices, no cost basis
No trims or exits this quarter.
Other tracked managers holding the same core names as Remedium Capital Partners, LLC
| Manager / fund | Shared names | Their $ in those |
|---|---|---|
| FMR LLC | 5 / 6 | $2.1B |
| Venrock Adviser, LLC | 5 / 6 | $1.2B |
| BlackRock, Inc. | 5 / 6 | $833.7M |
| VANGUARD CAPITAL MANAGEMENT LLC | 5 / 6 | $486.5M |
| VANGUARD GROUP INC | 5 / 6 | $455.0M |
| STATE STREET CORP | 5 / 6 | $406.7M |
| JANUS HENDERSON GROUP PLC | 5 / 6 | $388.0M |
| GEODE CAPITAL MANAGEMENT, LLC | 5 / 6 | $254.0M |
Ranked by how many of Remedium Capital Partners, LLC's top 6 disclosed names each fund also holds: a cross-fund conviction signal from the latest 13F of every tracked manager.
Bars show each stock's share of the portfolio. Click a row for its position history.
| # | Security | Value | Shares | % Port | Last move | History |
|---|---|---|---|---|---|---|
| 1 | Oruka Therapeutics Inc COM | $76.8M | 1.57M | 27.3% | ▲+0.8% Added · +13K sh | |
| 2 | Spyre Therapeutics Inc COM | $73.5M | 1.46M | 26.1% | —Held | |
| 3 | Damora Therapeutics Inc COM | $53.0M | 2.05M | 18.8% | ▲17× Added · +1.9M sh | |
| 4 | Apogee Therapeutics Inc COM | $49.1M | 583.6K | 17.5% | —Held | |
| 5 | Jade Biosciences Inc COM | $22.2M | 1.58M | 7.9% | —Held | |
| 6 | Crescent Biopharma Inc COM | $6.6M | 361.3K | 2.4% | —Held |
As-of date vs the date the SEC received each filing
| Quarter | As of | Filed | Positions | Value | Form |
|---|---|---|---|---|---|
| Q1 2026 | Mar 31, 2026 | May 19, 2026 | 6 | $281.2M | 13F-HR/A |
| Q4 2025 | Dec 31, 2025 | Feb 12, 2026 | 6 | $170.2M | 13F-HR |
Holdings from SEC EDGAR 13F-HR filings, updated quarterly ~45 days after quarter-end. Public domain. The book and weighting are long equity only; disclosed put/call options are listed separately and excluded from those totals. The performance line is a simulation of the disclosed long book, not an audited return.